Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): outcomes from the observational RE-MIND2 study

Results from the retrospective, observational RE-MIND2 study—presented during the 2021 Annual Meeting of the Society of Hematologic Oncology—demonstrated that tafasitamab plus lenalidomide may improve outcomes compared with other recommended therapies recommended used in routine clinical care for patients with relapsed/refractory DLBCL. Patients receiving tafasitamab/lenalidomide experienced longer overall survival versus those receiving systemic therapies pooled (HR, 0.553; P = .0076), bendamustine/rituximab (HR, 0.418; P < .0001), and rituximab/gemcitabine/oxaliplatin (HR, 0.467; P = .0004).